BioMarin Brand Guidelines: Novato 1997, Enzyme Therapies & the 2026 Amicus Deal

A rare-disease company from Marin County.

BioMarin was founded in 1997 by Christopher Starr and Grant W. Denison Jr., with start-up investment from Glyko Biomedical, English Wikipedia says; seed investors also included MPM Bioventures and Florian Schönharting, the Danish investor who in 1999 helped launch Genmab. The company’s own timeline dates its founding to March 1997 in Novato, California, with an initial focus on its proprietary enzyme technology, and records its first clinical trial, in a form of mucopolysaccharidosis (MPS), in December of the same year.

BioMarin went public in July 1999. The company says that because many of its early investors were in Europe, its shares were listed on both the Swiss SWX Exchange and the Nasdaq National Market. In 2002 it bought Glyko Biomedical, its original backer, English Wikipedia says. Its headquarters are now in San Rafael, in Marin County north of San Francisco, the same source says, with offices and facilities in the United States, South America, Europe and Asia. The company says it has about 3,000 employees and operates in about 80 countries, and in 2006 it set up BioMarin Europe Ltd., based in London.

Its core work is enzyme replacement therapy for inherited conditions. English Wikipedia describes BioMarin as the first company to provide a medicine for MPS type I, laronidase, sold as Aldurazyme and commercialised by Genzyme; BioMarin’s timeline dates the FDA authorisation of its first medicine for a form of MPS to April 2003, with European approval following that June. Jean-Jacques Bienaimé became chief executive in May 2005 and held the role for more than 18 years, the company says; Alexander Hardy succeeded him as president and chief executive in December 2023.

Enzymes, a peptide and a gene therapy.

English Wikipedia says that as of 2022 all of BioMarin’s marketed products were orphan drugs, medicines for rare conditions; the company now counts nine marketed products. They include Naglazyme (galsulfase), for Maroteaux–Lamy syndrome, or MPS VI; Kuvan (sapropterin), for phenylketonuria, introduced in 2007; Vimizim (elosulfase alfa), for Morquio A syndrome; and Brineura (cerliponase alfa), for a form of Batten disease, approved in 2017. The company’s timeline records an FDA approval in May 2005 for its first independently developed and commercialised medicine, a further MPS approval in February 2014, and an extension of its Batten disease medicine to children under three in July 2024.

The pipeline has reached beyond enzymes. At its R&D day in October 2010, English Wikipedia says, BioMarin announced vosoritide, a peptide programme for achondroplasia; the company’s timeline records an FDA approval in November 2021 for a therapy for a form of skeletal dysplasia, which it describes as the first medicine authorised for that growth-related condition. In February 2013 BioMarin licensed a gene therapy programme for an inherited bleeding disorder from University College London and St. Jude Children’s Research Hospital, the company says. That work led to Roctavian (valoctocogene roxaparvovec), for haemophilia A, which English Wikipedia says was approved in the EU in August 2022; the company dates its FDA approval to June 2023.

BioMarin also runs its own manufacturing. Its timeline says it completed the purchase of a manufacturing plant in Shanbally, in County Cork, Ireland, in 2011, and that the FDA approved the expansion of its biologics manufacturing facility in Novato that November. Pharmaceutical Technology referred to the company’s in-house manufacturing in April 2026.

Biotechnology identities.

Biotechnology companies sell things that are almost impossible to photograph. A medicine made from a strand of RNA or an engineered antibody has no shape a camera can see, so the sector leans on a small set of stand-in images: rendered molecules, ribbons and double helices, antibodies drawn as glowing Y-shapes, and close-ups of cells under a microscope. These macro images carry most of the visual weight on corporate websites, investor decks and annual reports.

The second familiar picture is the laboratory itself. Scientists at benches with pipettes, racks of sample tubes and gloved hands over a plate reader appear again and again, because they show work in progress rather than a finished product. Alongside them sit patient-advocacy portraits: people living with a rare disease, their families and the groups that represent them, photographed in everyday settings rather than in the clinic.

Architecture does the rest. Glass-fronted lab campuses in clusters such as Cambridge, Massachusetts, Copenhagen and South San Francisco stand in for scale and ambition, and company websites often show their buildings alongside their people. The calendar adds its own stage: the BIO International Convention and the J.P. Morgan Healthcare Conference, held each January in San Francisco, are where pipelines are presented to partners and investors.

Within that common language, names and colours do much of the work of telling companies apart. This guide sets out what can be checked about each brand — who founded it, where it is based, what it makes and what has happened to it — and marks clearly what rests only on the company’s own word. No product, logo or pack is reproduced, and the palettes are our own unofficial interpretation.

Acquisitions, access and Amicus.

BioMarin has grown through a run of acquisitions. In 2009 it bought Huxley Pharmaceuticals, whose amifampridine phosphate was approved by the European Commission in 2010 for Lambert–Eaton myasthenic syndrome and launched as Firdapse, English Wikipedia says. LEAD Therapeutics and ZyStor Therapeutics followed in 2010 and Zacharon Pharmaceuticals in 2012. In November 2014 the company agreed to buy the Dutch company Prosensa; its Duchenne muscular dystrophy treatments did not gain FDA approval, and development stopped in May 2016. In 2019 BioMarin said it would open an office in Dublin.

Its pricing and access decisions have drawn criticism, English Wikipedia records, including debates in 2013 and 2015 over expanded access to experimental drugs and a 2019 BBC report on access to Kuvan in England. In June 2019 a Belgian court, in a preliminary injunction, ordered the company to keep supplying Vimizim free of charge to a young patient until a final judgment or until the medicine was available in Belgium at a reasonable price.

The latest deals have widened the portfolio. In July 2025 BioMarin acquired Inozyme Pharma, adding a late-stage enzyme replacement therapy candidate for ENPP1 deficiency, the company says. In December 2025 it agreed to acquire Amicus Therapeutics, and Pharmaceutical Technology reported on 28 April 2026 that the purchase had been completed. It brought Galafold, for Fabry disease, and Pombiliti with Opfolda, for late-onset Pompe disease, along with US rights to DMX-200, an investigational medicine in Phase III trials.

For a design guide, BioMarin shows a rare-disease identity built over almost three decades of enzyme therapies, acquisitions and its own manufacturing. Compare Alnylam, another company focused on genetically defined conditions, and Biogen. For this guide we use a deep teal, a pale aqua and a soft coral with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep BioMarin’s identity on hand — save it to a board in the Made Good inspiration library.